The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models?
Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discovery
Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia
Disrupted-in-Schizophrenia-1 (DISC1) Interactome and Schizophrenia
Protein Interactions with Dopamine Receptors as Potential New Drug Targets for Treating Schizophrenia
Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophrenia
About this book
Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia.
Drug Discovery for Schizophrenia
covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing only on treating symptoms in patients. Innovative drugs emerge from deeper comprehension of the pathological processes that emerge earlier in life, hence, providing strategies for preventative therapy to alter the course of this mental disorder. Amongst other current topics, the book covers new findings in genetics and epigenetics, progress in animal models for schizophrenia and the usage of induced pluripotent stem cells. The combination of these important areas benefit psychiatric neuroscience, filling the gaps in the knowledge of neurobiology of schizophrenia and providing novel perspectives for future drug development.